Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

Bo Abrahamsen; Pia Eiken; Richard Eastell

doi:10.1210/jc.2010-1571

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

Bo Abrahamsen, Pia Eiken, Richard Eastell

139 Citations (Scopus)

Abstract

Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review.

Original language	English
Journal	The Journal of clinical endocrinology and metabolism
Volume	95
Issue number	12
Pages (from-to)	5258-65
Number of pages	8
DOIs	https://doi.org/10.1210/jc.2010-1571
Publication status	Published - 1 Dec 2010

Access to Document

10.1210/jc.2010-1571

Cite this

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. / Abrahamsen, Bo; Eiken, Pia; Eastell, Richard.
In: The Journal of clinical endocrinology and metabolism, Vol. 95, No. 12, 01.12.2010, p. 5258-65.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{64bf19d300a644f3a82f4298c27cacf9,

title = "Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis",

abstract = "Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review.",

author = "Bo Abrahamsen and Pia Eiken and Richard Eastell",

year = "2010",

month = dec,

day = "1",

doi = "10.1210/jc.2010-1571",

language = "English",

volume = "95",

pages = "5258--65",

journal = "The Journal of clinical endocrinology and metabolism",

issn = "1945-7197",

publisher = "Endocrine Society",

number = "12",

}

TY - JOUR

T1 - Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

AU - Abrahamsen, Bo

AU - Eiken, Pia

AU - Eastell, Richard

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review.

AB - Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review.

UR - https://www.scopus.com/pages/publications/78650038476

U2 - 10.1210/jc.2010-1571

DO - 10.1210/jc.2010-1571

M3 - Journal article

C2 - 20843943

SN - 1945-7197

VL - 95

SP - 5258

EP - 5265

JO - The Journal of clinical endocrinology and metabolism

JF - The Journal of clinical endocrinology and metabolism

IS - 12

ER -

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this